Day: January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

Read More   →

SANDF condemns gruesome Mozambique video

The South African National Defence Force (SANDF) says an investigation is underway into a video depicting South African soldiers as watching, as deceased bodies are thrown into a fire.According to a SANDF statement, the gruesome video – which has been…

Read More   →